Natera's fetal genetic testing trial enrolls over 2,000 patients
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
EXPAND Trial of Natera’s Fetal Focus™ Single-Gene NIPT Surpasses >2,000 Patients Enrolled
May 20, 2026 7:00 AM EDTMilestone follows prestigious oral plenary presentation of EXPAND data at SMFM Annual Meeting
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced that the EXPAND clinical trial has enrolled over 2,000 patients, more than doubling enrollment in the last 12 months.
EXPAND is a prospective, blinded, multi-site clinical trial designed to study Nateras Fetal Focus single-gene noninvasive prenatal test (NIPT). The trial was featured in an oral plenary session at the Society for Maternal-Fetal Medicine (SMFM) Annual Meeting in... More
